Last reviewed · How we verify
Male Patterned Baldness — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Propecia | finasteride | Merck & Co. | 5-alpha-reductase inhibitor | 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1, Cytochrome P450 2C19, Cytochrome P450 2C9 | 1992-06-19 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Merck & Co. · 1 drug in Male Patterned Baldness
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Male Patterned Baldness:
- Male Patterned Baldness treatment updates — RSS
- Male Patterned Baldness treatment updates — Atom
- Male Patterned Baldness treatment updates — JSON
Cite this brief
Drug Landscape (2026). Male Patterned Baldness — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/male-patterned-baldness. Accessed 2026-06-10.
Related
- Male Patterned Baldness full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing